HRYZ-T103

N/A

Report date: 2024/08/07 10:11:41

Base Information

Drug NameHRYZ-T103
Drug Alias NameHRYZ-T103
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsHead and Neck NeoplasmsOvarian NeoplasmsSarcoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesHRYZ Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHRYZ Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsHead and Neck NeoplasmsOvarian NeoplasmsSarcoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A